

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/512,024	05/09/2005	Abdullah Ibrahim Haj-Yehia	YISS2000100	2208
ABDULLAH I	7590 03/27/2007 HAI-VEHIA	EXAMINER		
47, P.O. BOX 168			FREISTEIN, ANDREW B	
NEVE SHALOM, 99761 ISRAEL			ART UNIT	PAPER NUMBER
			. 1626	
SHORTENED STATUTOR	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DAYS		03/27/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
	Application No.	HAJ-YEHIA, ABDULLAH IBRAHIM				
Office Action Summary	10/512,024 Examiner	Art Unit				
•	Andrew B. Freistein	1626				
The MAILING DATE of this communication app						
Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 26 Ja	nuary 2007.					
· ·	·					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
·						
Disposition of Claims						
4)⊠ Claim(s) <u>1-9 and 12-28</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) 1-9 and 12-28 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
,	,					
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) X Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate				
<ol> <li>Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date <u>4/7/2005</u>.</li> </ol>	5)  Notice of Informal F 6) Other:	'atent Application				
r aper No(s)/Mail Date 4///2003.	o,					

Art Unit: 1626

#### **DETAILED ACTION**

The restriction requirement mailed 09/28/2007 is <u>vacated</u>. It was in response to the original set of claims filed 10/19/2004 (claims 1-38).

The amendment filed 1/26/2007 was entered. Claims 1-9 and 12-28 are pending. Claims 10, 11 and 29-38 were cancelled.

### Priority

This application is a 371 of PCT/IL03/00312, filed 04/15/2003 and claims benefit of US Provisional Application No. 60/374,173, filed 04/19/2002.

# Information Disclosure Statement

Applicant's information disclosure statement (IDS), filed on 04/07/2005, has been considered. Please refer to Applicant's copies of the 1449 submitted herewith.

### Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

### Lack of Unity Requirement

Claims 1-9 and 12-28 are drawn to more than one inventive concept (as defined by PCT Rule 13), and accordingly, a restriction is required according to the provision of PCT Rule 13.2.

PCT Rule 13.2 states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (requirement of unity of invention).

Application/Control Number: 10/512,024

Art Unit: 1626

PCT Rule 13.2 states unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, Part 1 (b), provides that "special technical features" mean those technical features, which, as a whole, define a contribution over the prior art.

Annex B, Part 1 (e), provides combinations of different categories of claims and states:

"The method for determining unity of invention under Rule 13 shall be construed as permitting, in particular, the inclusion of any one of the following combinations of claims of different categories in the same international application:

- (i) in addition to an independent claim for a given product, an independent claims for a process specially adapted for the manufacture of the said product, and an independent claim for use of the said product, or
- (ii) in addition to an independent claim for a given process, an independent claim for an apparatus or means specially designed for carrying out the said process, or
- (iii) in addition to an independent claim for a given product, and independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for an apparatus or means specially designed for carrying out the said process,..."

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I: Claims 1-9 and 23-25, drawn to a product of formula (I).

Group II: Claims 12-14, drawn to a process for preparing a product of formula (I).

Group III: Claim 15, drawn to a composition comprising a compound of formula

(I) for use as a medicament.

**Group IV**: Claims 16-22 and 26, drawn to a method for treating or preventing a respiratory disorder.

**Group V**: Claim 27, drawn to an inhalation device for administering a compound of formula (I).

**Group VI**: Claim 28, drawn to a kit comprising an inhalation device device for administering a compound of formula (I).

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: they do not share the same structural element(s) that define the "special technical feature" necessary to specify a contribution over the prior art.

technical feature is not a special technical feature, because it fails to define a contribution over the prior art. For example, see Johansson et al., " $\beta_2$ -Adrenoceptor selectivity in four series of  $\beta$ -adrenoceptor agonists," <u>European Journal of</u> Pharmacology, Vol. 130(1-2), pp. 97-103 (1986), which discloses the compound:

Therefore, claims 1-9 and 12-28 are not so linked as to form a single general inventive concept and there is a lack of unity of invention. The variables vary extensively and when taken as a whole result in vastly different compounds.

Additionally, the vastness of the claimed subject matter and the complications in understanding the claimed subject matter impose a serious burden on any examination of the claimed subject matter.

Because the claims do not relate to a single general inventive concept under PCT Rule 13.1 and lack the same or corresponding special technical features, the claims lack unity of invention and should be limited to <u>a</u> product, <u>a</u> process for the manufacture of said product, or <u>a</u> method of use.

Furthermore, with respect to Groups I-VI, even if unity of invention under 37 CFR 1.475(a) is not lacking, under 37 CFR 1.475(b) a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specially designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specially designed for carrying out the said process.

Moreover, according to 37 CFR 1.475(c),

If an application contains claims to more or less that one of the combinations of categories of invention set forth in paragraph (b), unity of invention might not be present.

In the instant case the claims are drawn to more than one product, process, and method of use. According to 37 CFR 1.475(e),

The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

A telephone call was made to Attorney Kevin McCarthy on March 20, 2007 but it did not result in an election being made.

## Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew B. Freistein whose telephone number is (571) 272-8515. The examiner can normally be reached Monday-Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M<sup>c</sup>Kane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Application/Control Number: 10/512,024

Art Unit: 1626

Page 7

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Andrew B. Freistein Patent Examiner, AU 1626 Joseph K. M<sup>⊆</sup>Kane

Supervisory Patent Examiner, AU 1626

Date: March 20, 2007

KAMALA. SAZZD, PH.D. FRIMARY EXAMINER